Inmunoterapia en 1L del CPCNP: monoterapia y/o tratamiento combinado - page 40

4. Nuevas combinaciones

Herbst R et al. ESMO 2016

ORR=30%; DCR=85%

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1...,30,31,32,33,34,35,36,37,38,39 41,42